Search hospitals > Texas > Fort Worth
Cook Children's Medical Center
Claim this profileFort Worth, Texas 76104
Global Leader in T-Lymphoblastic Leukemia/Lymphoma
Global Leader in Neuroblastoma
Conducts research for Uterine Tumors
Conducts research for Acute Lymphoblastic Leukemia
Conducts research for Lymphoma
488 reported clinical trials
18 medical researchers
Summary
Cook Children's Medical Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Neuroblastoma, Uterine Tumors, Acute Lymphoblastic Leukemia, Lymphoma and other specialties. Cook Children's Medical Center is involved with conducting 488 clinical trials across 652 conditions. There are 18 research doctors associated with this hospital, such as Kelly L. Vallance, Kenneth M. Heym, Sibo Zhao, MD, and Mary Meaghan P. Granger.Area of expertise
1T-Lymphoblastic Leukemia/Lymphoma
Global LeaderStage II
Stage I
t(8;21)(q22;q22) positive
2Neuroblastoma
Global LeaderMYC positive
Stage IV
MYC negative
Top PIs
Kelly L. VallanceCook Children's Medical Center7 years of reported clinical research
Expert in Uterine Tumors
Expert in Cancer
20 reported clinical trials
35 drugs studied
Kenneth M. HeymCook Children's Medical Center8 years of reported clinical research
Expert in T-Lymphoblastic Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
17 reported clinical trials
58 drugs studied
Sibo Zhao, MDCook Children's Medical Center5 years of reported clinical research
Studies Cerebral Gliomas
Studies Brain Cancer
10 reported clinical trials
25 drugs studied
Mary Meaghan P. GrangerCook Children's Medical Center4 years of reported clinical research
Studies Neuroblastoma
Studies Cancer
9 reported clinical trials
23 drugs studied
Clinical Trials running at Cook Children's Medical Center
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Cancer
T-Lymphoblastic Leukemia/Lymphoma
Uterine Tumors
Testicular cancer
Wilms Tumor
Brain Cancer
Lymphoma
Brain Tumor
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Tagraxofusp
for Blood Cancers
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Recruiting1 award Phase 1
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Cook Children's Medical Center?
Cook Children's Medical Center is a medical facility located in Fort Worth, Texas. This center is recognized for care of T-Lymphoblastic Leukemia/Lymphoma, Neuroblastoma, Uterine Tumors, Acute Lymphoblastic Leukemia, Lymphoma and other specialties. Cook Children's Medical Center is involved with conducting 488 clinical trials across 652 conditions. There are 18 research doctors associated with this hospital, such as Kelly L. Vallance, Kenneth M. Heym, Sibo Zhao, MD, and Mary Meaghan P. Granger.
Where is Cook Children's Medical Center located?
Cook Children's Medical Center, situated at 801 7th Ave, Fort Worth, Texas, is a leading not-for-profit pediatric hospital featuring 430 beds and a Level II pediatric trauma center. It provides comprehensive pediatric specialties and subspecialties, such as a Level IV neonatal intensive care unit and a nationally accredited heart center. Esteemed for its excellence, the hospital is consistently ranked among the nation's top children's hospitals by U.S. News & World Report.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Cook Children's Medical Center, contact their financial team at 682-885-4000 or visit [www.cookchildrens.org/patients-families/billing-insurance/financial-assistance/](www.cookchildrens.org/patients-families/billing-insurance/financial-assistance/). They provide support for uninsured or underinsured children, including CHIP, Medicaid, and their health plan company, and offer financial aid for families ineligible for government programs. For insurance inquiries, visit the Cook Children's Health Plan website at [www.cookchildrenshealthplan.org](www.cookchildrenshealthplan.org) or email CommunityMarketing@cookchildrens.org for application assistance.
What insurance does Cook Children's Medical Center accept?
Cook Children's Medical Center accepts a wide range of insurance plans, including but not limited to Children's Medical Center Health Plan, Cook Children's Health Plan, Aetna, and Blue Cross Blue Shield of Texas. Not all plans are accepted by all affiliated companies of Cook Children's Health Care, and some plans may not cover specific services. Cook Children's does not accept Healthcare Sharing Ministry Plans, Physicians Only Product, or Referenced based pricing plans.
What awards or recognition has Cook Children's Medical Center received?
Cook Children's Medical Center, located in Fort Worth, Texas, is renowned for its exceptional pediatric healthcare services. The center has been honored with the Silver Beacon Award for Excellence by the American Association of Critical-Care Nurses and the 2023 Press Ganey Guardian of Excellence Award® for its unwavering commitment to patient care. Furthermore, it has been awarded a $2.3 million R01 research project grant by the National Institute of Neurological Disorders and Stroke of the NIH to advance pediatric epilepsy diagnosis.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.